MELISSA GENTRY: Open Payments
NPI 1538153846 · OSKALOOSA, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$982 in 48 payments from 16 companies in 2025. Trend: 2023 $1,079 · 2024 $2,970 · 2025 $982
Food & beverage: $982
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $178 |
| Vanda Pharmaceuticals Inc. | 4 | $108 |
| Lundbeck LLC | 4 | $100 |
| Neurocrine BioSciences, Inc. | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Itamar Medical Inc | 1 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $66 |
| Corium, LLC | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
Products named: REXULTI, VRAYLAR, FANAPT, INGREZZA, WatchPATONE, CAPLYTA, Azstarys, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
